Product Data Sheet

Brilliant Violet 650[™] anti-human CD16

Catalog # / Size:	2110205 / 25 tests 2110210 / 100 tests	1
Clone:	3G8	1
Isotype:	Mouse IgG1, к	age .
Immunogen:	Human PMN cells	Relative Cell Number
Reactivity:	Human	he Co
Preparation:	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 650 [™] under optimal conditions. The solution is free of unconjugated Brilliant Violet 650 [™] and unconjugated antibody.	0 10 ² 10 ³ 10 ⁴ 10 ⁵ Log Fluorescence Intensity
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).	Human peripheral blood lymphocytes were stained with CD16 (clone 3G8) Brilliant Violet
Workshop Number:	V NK80	650™.
Concentration:	Lot-specific	

Applications:

Applications:	Flow Cytometry
---------------	----------------

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 650[™] excites at 405 nm and emits at 645 nm. The bandpass filter 660/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 650[™] is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: The 3G8 antibody blocks neutrophil phagocytosis and stimulates NK cell proliferation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections⁶, immunoprecipitation3, stimulation of NK cell proliferation4, blocking of phagocytosis5, and blocking of immunoglobulin binding to FcγRIII^{7,8}. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302014). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 302050) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01</p>

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com EU/microg).

Application References:	 Knapp W, <i>et al.</i> Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York. Schlossman S, <i>et al.</i> Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. Edberg J, <i>et al.</i> 1997. <i>J. Immunol.</i> 159:3849. (IP) Hoshino S, <i>et al.</i> 1991. <i>Blood</i> 78:3232. (Stim) Tamm A, <i>et al.</i> 1996. <i>Immunol.</i> 157:1576. (Block) Da Silva DM, <i>et al.</i> 2001. <i>Int. Immunol.</i> 13:633. (IHC) Holl V, <i>et al.</i> 2004. <i>J. Immunol.</i> 173:6274. (Block) Hober D, <i>et al.</i> 2002. <i>J. Gen. Virol.</i> 83:2169. (Block) Brainard DM, <i>et al.</i> 2009. <i>J. Virol.</i> 83:7305. PubMed Smed-Sörensen A, <i>et al.</i> 2008. <i>J. Leukoc. Biol.</i> 84:1271. (FC) PubMed Timmerman KL, <i>et al.</i> 2008. <i>J. Leukoc. Biol.</i> 84:1271. (FC) Rout N, <i>et al.</i> 2010. <i>PLoS One</i> 5:e9787. (FC) Kim WK, <i>et al.</i> 2001. <i>J. Biol Chem.</i> 286:21896. PubMed Wu Z, <i>et al.</i> 2013. <i>J. Virol.</i> 87:7717. PubMed
	15. Boltz A, <i>et al.</i> 2011. <i>J. Biol Chem.</i> 286:21896. <u>PubMed</u> 16. Wu Z, <i>et al.</i> 2013. <i>J. Virol.</i> 87:7717. <u>PubMed</u>

Description: CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC).

 Antigen
 1. Fleit H, et al. 1982. P. Natl. Acad. Sci. USA 79:3275.

 References:
 2. Stroncek D, et al. 1991. Blood 77:1572.

 3. Wirthmueller U, et al. 1992. J. Exp. Med. 175:1381.